

March 2016

Performance figures show that the UK is open for business

UK'S CLINICAL RESEARCH NETWORK ACHIEVES 65 FIRST GLOBAL PATIENTS IN THREE YEARS

The National Institute for Health Research (NIHR) Clinical Research Network has reached a milestone in study set-up achievements by recruiting 65 first global patients in commercial studies in the last three years.

With many clinical research studies recruiting patients simultaneously from all over the world, a “global first patient” is a key performance indicator for the life-sciences industry. It demonstrates which countries can support the rapid set-up of studies.

Since the Network started to record first global patients, it has achieved 86 in total. Over the last five years the Network has also seen an upturn in the number of studies coming into the country, 623 new commercial contract studies last year, no doubt helped by this achievement. This is a signal that the UK is now a globally competitive market in which to conduct clinical research.

These achievements are primarily the result of the work undertaken to improve study set-up times. The Network has reduced the time taken for studies to get underway by 82 per cent over the last five years. The median number of calendar days taken to obtain permission from National Health Service (NHS) sites was 20 days in 2014/15 compared to 115 days in 2010/11.

Commenting on the news, Dr Jonathan Sheffield, Chief Executive Officer of the NIHR Clinical Research Network, said:

“Achieving a first global patient shows that the UK has the infrastructure to compete on the international stage in terms of clinical research study set-up. The Network is driving down the time it takes to set up a study in the UK and this in turn is being rewarded with a record number of these achievements.”

Paul Duffy, Executive Director Clinical Research UK & ROI, MSD (known as Merck in the US and Canada) said:

“Rapid study set up is integral to attracting new clinical trials and companies to the UK, and is a key element of the UK Government’s strategy for UK Life Sciences. We have seen an 80 per cent increase in the number of studies coming into the UK in the past two years. Our growing relationship with NIHR has played a key role by helping to facilitate quicker set-up time for MSD studies throughout the UK.”

Dr Matt Cooper, Business Development and Marketing Director of the NIHR Clinical Research Network, said:

“The commercial research landscape here has changed dramatically over recent years and our performance figures show that the UK is well and truly open for business. These changes are helping to drive growth and investment but, more importantly, they also mean that patients using our National Health Service are getting access to cutting edge treatments and technologies sooner.”

More than 100,000 people have participated in commercial contract research supported by the NIHR Clinical Research Network over the last five years. Last financial year the Network recruited nearly 35,000 participants to studies sponsored by the life-sciences industry – a 35 per cent increase on the previous year.

These improvements are also testament to the ongoing work of the wider NIHR (www.nihr.ac.uk) - the research arm of the UK's National Health Service (NHS). The NIHR celebrates its 10th anniversary this year. It is funded by the UK Government and invests over £1 billion per year into research programmes, projects and research infrastructure in England. The NIHR plays a key role in the Government's strategy for economic growth, attracting investment by the life-sciences industries through its world-class infrastructure for health research which represents the most integrated health research system in the world.

Dr Matt Cooper, Business Development and Marketing Director for the NIHR Clinical Research Network, will be giving a 20 minute case study presentation on day one of the BioPharmAsia Convention 2016 Clinical Trials Session ([read Matt Cooper's biography](#)). Entitled “Looking west - The UK as a clinical trial destination”, Dr Cooper's session will describe how the UK's clinical research environment has evolved to make the achievements listed here possible.

The NIHR Clinical Research Network team will be available to meet with delegates at exhibition stand B22 throughout the event. If you would like to arrange a one to one meeting please use the contacts below:

Dr Teresa Fortune, Head of Business Development and Marketing, t. [+44 \(0\)7881337362](tel:+44207881337362) | e. teresa.fortune@nihr.ac.uk

Alternatively you can see a full list of studies that have achieved first global patient and find out more about our Study Support Service by visiting www.crn.nihr.ac.uk/biopharmaasia



Research delivery in the NHS

2014-2015


The NIHR Clinical Research Network is funded by the Department of Health to deliver a portfolio of high-quality clinical research in the NHS in England. Here are the key statistics for 2014-15.



OVER 3 MILLION PARTICIPANTS IN 5 YEARS

More than **618,000 people** participated in clinical research studies last year. This means that over the last five years more than **three million people** have had the opportunity to participate in research supported by the Network.

Nearly **35,000 participants** were recruited to studies sponsored by the life sciences industry last year. This increased by 35 per cent in just one year, with more than **100,000 people** participating in commercial contract research over the last five years.



IMPROVED STUDY SET-UP AND DELIVERY

The Network is supporting studies to set up more rapidly, with **83 per cent** of studies now receiving NHS permission within 40 days at all sites. The median number of days to achieve NHS Permission is now **20 calendar days**.

The Network continues to demonstrate that the UK is internationally competitive in speed of study set-up by recruiting **global first patients** into multiple studies.

The Network has more than doubled the proportion of all clinical studies delivered to time and recruitment target since 2010-11.



INCREASED INVESTMENT IN NHS CLINICAL RESEARCH

The number of new studies supported by the NIHR Clinical Research Network continues to grow, with the most significant increase in new studies sponsored by the life sciences industry.

In 2014-15 the Network supported delivery of **1,869 new studies** with 623 of these from the life sciences industry. This is an average annual increase in new commercial contract studies of 18 per cent.



NHS ENGAGEMENT

Last year **98 per cent** of NHS Trusts and **41 per cent** of General Medical Practices were actively engaged in clinical research. In addition, **78 per cent** of NHS Trusts were supporting patient opportunities to participate in commercial contract research.



INCREASED OPPORTUNITIES TO PARTICIPATE IN DEMENTIA RESEARCH

The Network continues to support the Government's Dementia Challenge and in 2014-15 supported nearly **21,500 people** to participate in clinical research associated with dementias and neurodegeneration.

2014-2015 年间

在英国国家医疗服务体系内开展的研究



National Institute for
Health Research

Clinical Research Network

NIHR 临床研究网络由卫生部资助，在英国国家医疗服务体系内开展一系列高品质的临床研究。这是 2014-2015 年间的重要统计资料。

5 年内，逾 3 百万参与者

去年，逾 **618,000** 人参与了临床研究性工作。这意味着在过去五年内，逾 **3 百万** 人有机会参与该网络支持的研究。



去年，由生命科学行业赞助的研究招募了近 **35,000 名参与者**。在过去五年，逾 **100,000** 人参与了商业合约研究，而这一数字仅在去年一年就增加了 35%。

研究启动和开展得以完善

该网络支持更快速地启动研究，现在，在所有站点，**83%** 的研究能在 40 天内获得英国国家医疗服务体系的许可。现在，获得英国国家医疗服务体系许可所需天数的均值为 **20 个日历日**。



该网络再次证明，在通过招募**全球首例患者**参与多重研究以启动研究的速度方面，英国具有国际性竞争力。

自 2010-2011 年以来，通过该网络按时间线开展的所有临床研究和招募的目标的比例已超出两倍。

对英国国家医疗服务体系内的临床研究增加投资

由 NIHR 临床研究网络支持的新研究的数量持续增长，其中，意义最为重大的数量增长由生命科学行业赞助。



在 2014-2015 年间，该网络支持开展了 **1,869 项新研究**，其中 623 项来自生命科学行业。新的商业合约研究平均每年增长 18%。



英国国家医疗服务体系的支持

去年，**98%** 的英国国家医疗服务体系信托基金机构和 **41%** 的一般医疗规范为临床研究提供积极支持。另外，**78%** 的英国国家医疗服务体系信托基金机构为患者提供参与商业合约研究的机会。



增加的参与研究的机会

该网络继续支持政府的痴呆症激发项目，并且在 2014-2015 年间，支持近 **21,500** 人参加与痴呆症和神经退行性疾病相关的临床研究。